Levulinic acid-13C3
Levulinic acid-13C3 (4-Oxovaleric acid-13C) is the 13C-labeled Levulinic acid (HY-Y0839). Levulinic acid is a precursor for the synthesis of biofuels, such as ethyl levulinate. Levulinic acid is also a 5-keto-pentanoic acid. Levulinic acid can be utilized by the cells as a cosubstrate for biopolymer synthesis. Levulinic acid can be used in antibacterial research.
For research use only. We do not sell to patients.
- CAS No.: 1391051-93-6
- Formula: C213C3H8O3
- Molecular Weight:119.09
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Application
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1391051-93-6
-
Unlabeled CAS 123-76-2
-
Molecular Weight 119.09
-
Formula C213C3H8O3
-
SMILES
[13CH3][13C]([13CH2]CC(O)=O)=O
-
Synonyms
4-Oxovaleric acid-13C3; NSC 3716-13C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)